Intellia Therapeutics (NASDAQ:NTLA) Releases Quarterly Earnings Results, Meets Estimates

Intellia Therapeutics (NASDAQ:NTLA) released its quarterly earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.80), FiscalAI reports. The business had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 58.80%. Intellia Therapeutics’s revenue for the quarter was down 46.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.98) EPS.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• Lonvo-z’s phase III HALO trial succeeded, showing an 87% reduction in mean monthly HAE attacks versus placebo, with 62% of patients attack-free and therapy-free during the six-month evaluation period. Intellia expects FDA acceptance of the rolling BLA by year-end and is preparing for a potential U.S. launch in the first half of 2027.
• Nex-z phase III enrollment and dosing resumed in both ATTR trials during the second quarter after clinical holds were resolved, with screening rates increasing globally. Intellia reported that MAGNITUDE has enrolled more than 650 patients and that blinded event rates remain within its internal projections.
• Intellia identified the HLA-C*05:01 allele as associated with a significantly higher rate of severe transaminase elevations following nex-z treatment. The allele is present in roughly 12% of patients, although most carriers did not experience severe elevations; updated protocols now require HLA typing and enhanced risk disclosure.
• The company ended June with $628.4 million in cash, equivalents, and marketable securities after raising approximately $195 million in net proceeds through an April equity financing. Management believes this provides a cash runway into at least 2028, excluding potential lonvo-z product revenue.
• Second-quarter collaboration revenue declined to $7.7 million from $14.2 million year over year, while net loss widened to $106.6 million from $101.3 million. R&D expenses fell, but G&A increased due to commercial infrastructure build-out, legal costs, and higher stock-based compensation.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA traded up $0.70 during trading hours on Friday, hitting $11.94. 4,923,615 shares of the company’s stock were exchanged, compared to its average volume of 4,163,880. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -3.55 and a beta of 1.81. The company’s 50-day moving average price is $13.65 and its 200-day moving average price is $13.48. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25.

Insider Activity at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.50% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the period. State Street Corp raised its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after acquiring an additional 1,447,967 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Intellia Therapeutics by 156.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,672,700 shares of the company’s stock worth $15,038,000 after acquiring an additional 1,021,700 shares during the period. HRT Financial LP bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth approximately $6,876,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Intellia Therapeutics by 1,076.6% in the 4th quarter. BNP Paribas Financial Markets now owns 591,277 shares of the company’s stock worth $5,316,000 after acquiring an additional 541,026 shares during the period. 88.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NTLA. Wedbush upped their price objective on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. New Street Research set a $25.00 target price on Intellia Therapeutics in a report on Monday, June 15th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a research report on Friday. Finally, Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.85.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing a favorable “nex-z hypothesis.” The upgrade suggests the firm sees greater potential in Intellia’s gene-editing pipeline, providing the clearest positive catalyst in the recent news flow. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets raised its fourth-quarter 2026 EPS forecast to a loss of $0.41 from $0.47, while projecting a path to profitability beginning in 2027. That outlook supports the longer-term investment case, although the firm made broader reductions to its estimates. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating the firm sees neither a sufficiently strong near-term catalyst nor enough downside to change its stance. Bank of America Securities remains a Hold on Intellia Therapeutics
• Negative Sentiment: Intellia’s second-quarter loss was in line with expectations, but revenue fell about 46% year over year to $7.66 million, missing estimates of roughly $12.98 million. The decline was attributed to lower revenue from the Regeneron collaboration, highlighting the company’s reliance on partnership income while it continues to spend heavily on research and development. NTLA Q2 earnings in line, top line misses on lower Regeneron revenues
• Negative Sentiment: Brookline lowered its estimates for the second and third quarters of 2026 and reduced its full-year 2026 forecast to a $2.84 per-share loss. More significantly, projected EPS was cut for 2027 through 2030, including a reduction in 2030 estimates from $68.52 to $25.07, signaling lower expectations for the eventual commercial opportunity.
• Negative Sentiment: WallStreetZen downgraded NTLA to Strong Sell, adding to the bearish analyst commentary and reinforcing concerns about continued losses, execution risk and valuation. Intellia lowered to Strong Sell rating

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.